Interleukin-12 from CD103+ Batf3-dependent dendritic cells required for NK-cell suppression of metastasis

Cancer Immunology Research

Volumn 5, Issue 12, 2017, Pages 1098-1108

  Mittal, Deepak ^a   Vijayan, Dipti ^a   Putz, Eva M ^a   Aguilera, Amelia R ^a   Markey, Kate A ^a,b   Straube, Jasmin ^a   Kazakoff, Stephen ^a   Nutt, Stephen L ^c   Takeda, Kazuyoshi ^d   Hill, Geoffrey R ^a,b   Waddell, Nicola ^a   Smyth, Mark J ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; GAMMA INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 12; NATURAL KILLER CELL RECEPTOR; PROTEIN; PROTEIN BATF3; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG; ALPHA E INTEGRINS; ALPHA INTEGRIN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BIOLOGICAL MARKER; INTERFERON REGULATORY FACTOR; LEUKOCYTE ANTIGEN; REPRESSOR PROTEIN; SNFT PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B16-BL6 CELL LINE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; GENE EXPRESSION; HUMAN; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; METASTASIS; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STATISTICAL SIGNIFICANCE; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; DEFICIENCY; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; KNOCKOUT MOUSE; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; PROGNOSIS;

ANIMALS; ANTIGENS, CD; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BIOMARKERS; DENDRITIC CELLS; GENE EXPRESSION; HUMANS; IMMUNOMODULATION; INTEGRIN ALPHA CHAINS; INTERFERON REGULATORY FACTORS; INTERLEUKIN-12; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; REPRESSOR PROTEINS;

EID: 85037672863     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-17-0341     Document Type: Article

References (43)

1. Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016;6:71–9.
2. Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(þ) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 2016;44:924–38.
3. Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res 2017;27: 96–108.
4. Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol 2016;37:855–65.
5. Desch AN, Randolph GJ, Murphy K, Gautier EL, Kedl RM, Lahoud MH, et al. CD103þ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med 2011;208:1789–97.
6. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012;12:557–69.
7. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alphaþ dendritic cells in cytotoxic T cell immunity. Science 2008;322:1097–100.
8. Mashayekhi M, Sandau MM, Dunay IR, Frickel EM, Khan A, Goldszmid RS, et al. CD8alpha(þ) dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites. Immunity 2011;35:249–59.
9. Ashok D, Schuster S, Ronet C, Rosa M, Mack V, Lavanchy C, et al. Cross-presenting dendritic cells are required for control of Leishmania major infection. Eur J Immunol 2014;44:1422–32.
10. þ dendritic cells are induced in neonates upon Listeria monocytogenes infection. PLoS Pathog 2016;12:e1005561.
11. þ dendritic cells suppress helminth-driven type 2 immunity through constitutive expression of IL-12. J Exp Med 2016;213: 35–51.
12. Break TJ, Hoffman KW, Swamydas M, Lee CC, Lim JK, Lionakis MS. Batf3-dependent CD103(þ) dendritic cell accumulation is dispensable for mucosal and systemic antifungal host defense. Virulence 2016;7:826–35.
13. þ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice. Eur J Immunol 2015;45:119–29.
14. Waithman J, Zanker D, Xiao K, Oveissi S, Wylie B, Ng R, et al. Resident CD8 (þ) and migratory CD103(þ) dendritic cells control CD8 T cell immunity during acute influenza infection. PLoS One 2013;8:e66136.
15. Zitvogel L, Kroemer G. CD103þ dendritic cells producing interleukin-12 in anticancer immunosurveillance. Cancer Cell 2014;26:591–3.
16. James BR, Brincks EL, Kucaba TA, Boon L, Griffith TS. Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8alpha dendritic cells. Cancer Immunol Immunother 2014;63:685–97.
17. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014;26:638–52.
18. Teng MW, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Moller A, et al. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci USA 2010;107: 8328–33.
19. Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard K, et al. Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Res 2016;76:4372–82.
20. þ dendritic cells from mouse bone marrow. Blood 2014;124: 3081–91.
21. Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014;15:431–8.
22. Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using tran-scriptomic data of 1,065 patients. Oncotarget 2016;7:49322–33.
23. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15–21.
24. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139–40.
25. Chopin M, Seillet C, Chevrier S, Wu L, Wang H, Morse HC 3rd, et al. Langerhans cells are generated by two distinct PU.1-dependent transcriptional networks. J Exp Med 2013;210:2967–80.
26. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011;208:2005–16.
27. Takeda K, Nakayama M, Sakaki M, Hayakawa Y, Imawari M, Ogasawara K, et al. IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukoc Biol 2011;90:777–85.
28. Martinet L, Ferrari De Andrade L, Guillerey C, Lee JS, Liu J, Souza-FonsecaGuimaraes F, et al. DNAM-1 expression marks an alternative program of NK cell maturation. Cell Rep 2015;11:85–97.
29. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004;104:3267–75.
30. Hafner M, Falk W, Echtenacher B, Mannel DN. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity. Eur Cytokine Netw 1999;10:541–8.
31. Takeda K, Hayakawa Y, Atsuta M, Hong S, Van Kaer L, Kobayashi K, et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 2000;12:909–14.
32. Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014;63:419–35.
33. Jaiswal H, Kaushik M, Sougrat R, Gupta M, Dey A, Verma R, et al. Batf3 and Id2 have a synergistic effect on Irf8-directed classical CD8alphaþ dendritic cell development. J Immunol 2013;191:5993–6001.
34. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192–7.
35. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405–11.
36. Mott KR, Maazi H, Allen SJ, Zandian M, Matundan H, Ghiasi YN, et al. Batf3 deficiency is not critical for the generation of CD8alpha(+) dendritic cells. Immunobiology 2015;220:518–24.
37. Murphy TL, Tussiwand R, Murphy KM. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol 2013;13:499–509.
38. Seillet C, Jackson JT, Markey KA, Brady HJ, Hill GR, Macdonald KP, et al. CD8alphaþ DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3. Blood 2013;121:1574–83.
39. Tussiwand R, Lee WL, Murphy TL, Mashayekhi M, Kc W, Albring JC, et al. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 2012;490:502–7.
40. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1:1074–83.
41. Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, et al. NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci USA 2015;112:E2376–84.
42. Guillerey C, Chow MT, Miles K, Olver S, Sceneay J, Takeda K, et al. Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. Oncoimmunology 2015;4: e1027468.
43. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol 1998;161:6164–70.